Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
NOVATO, Calif., Jan. 04, 2024 -- Ultragenyx Pharmaceutical Inc. today announced that the National Institute for Health and Care Excellence has issued a final draft guidance recommending Evkeeza®...
Source: marketscreener.com